{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05444894",
            "orgStudyIdInfo": {
                "id": "EM-301-BThal-001"
            },
            "organization": {
                "fullName": "Editas Medicine, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)",
            "officialTitle": "A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "edit-for-autologous-hematopoietic-stem-cell-transplant-hsct-in-participants-with-transfusion-dependent-beta-thalassemia-tdt"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-04-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-06-27",
            "studyFirstSubmitQcDate": "2022-07-01",
            "studyFirstPostDateStruct": {
                "date": "2022-07-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Editas Medicine, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia",
            "detailedDescription": "This is a Phase 1/2 single-arm, open-label, multicenter study evaluating the safety, tolerability, and efficacy of a single unit dose of EDIT-301 for autologous hematopoietic stem cell transplant in adult participants with TDT, age 18 to 35 years, inclusive"
        },
        "conditionsModule": {
            "conditions": [
                "Transfusion Dependent Beta Thalassemia",
                "Hemoglobinopathies",
                "Thalassemia Major",
                "Thalassemia Intermedia"
            ],
            "keywords": [
                "Beta-Thalassemia",
                "Hemoglobinopathies",
                "CRISPR-Cas 12a",
                "Autologous CD34+"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 9,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "EDIT-301",
                    "type": "EXPERIMENTAL",
                    "description": "EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.",
                    "interventionNames": [
                        "Genetic: EDIT-301"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "EDIT-301",
                    "description": "Administered by intravenous infusion after myeloablative conditioning with busulfan.",
                    "armGroupLabels": [
                        "EDIT-301"
                    ],
                    "otherNames": [
                        "renizgamglogene autogedtemcel",
                        "reni-cel"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of participants achieving engraftment defined as neutrophil engraftment (defined as demonstrating absolute neutrophil count (ANC) \u2265 0.5 x 10^9/L post EDIT-301 infusion for 3 consecutive measurements obtained on different days)",
                    "timeFrame": "EDIT-301 infusion (Day 0) to 42 days post EDIT-301 infusion"
                },
                {
                    "measure": "Frequency and severity of adverse events (AEs) (incidence of AEs and Grade 3 or higher serious adverse events, using National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v.5.0)",
                    "timeFrame": "Screening through up to 24 months post EDIT-301 infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Kinetics of HSPC engraftment",
                    "description": "Time to neutrophil engraftment",
                    "timeFrame": "EDIT-301 infusion (Day 0) to first day in which 3 consecutive measurements obtained on different days demonstrate ANC \u2265 0.5 x 10^9/L up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Kinetics of HSPC engraftment",
                    "description": "Time to platelet engraftment",
                    "timeFrame": "EDIT-301 infusion (Day 0) to first day of 3 consecutive measurements of platelets \u2265 50 x 10^9/L for at least 1 week following the last platelet transfusion and 10 days following thrombopoietin mimetics use up to 24 months post EDIT-301 infusion."
                },
                {
                    "measure": "Incidence of transplant related mortality",
                    "timeFrame": "EDIT-301 infusion (Day 0) through Day 100 post EDIT-301 infusion and from EDIT-301 infusion (Day 0) through 12 months post EDIT-301 infusion"
                },
                {
                    "measure": "Incidence of all-cause mortality",
                    "timeFrame": "Screening through up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Proportion of alleles per participant with intended genetic modification present in peripheral blood over time",
                    "timeFrame": "EDIT-301 infusion (Day 0) through up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Proportion of alleles per participant with intended genetic modification present in bone marrow cells over time",
                    "timeFrame": "EDIT-301 infusion (Day 0) through up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Change in the fetal hemoglobin (HbF) concentration compared to baseline overtime",
                    "timeFrame": "Baseline through up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Change in the total hemoglobin concentration compared to baseline overtime",
                    "timeFrame": "Baseline through up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Proportion of participants with hemoglobin concentration \u2265 9 g/dL",
                    "timeFrame": "EDIT-301 infusion (Day 0) through 3, 6, 12 months up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Proportion of participants achieving the sustained transfusion reduction (TR) for at least 6 months and at least 12 months from 3 months post-EDIT-301 infusion",
                    "timeFrame": "3 months post EDIT-301 infusion through up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Proportion of participants achieving the sustained transfusion independence (TI) for at least 6 months and, at least 12 months from 3 months post EDIT-301 infusion",
                    "timeFrame": "3 months through up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Change in parameters of iron overload compared to baseline over time",
                    "timeFrame": "Baseline through up to 24 months post EDIT-301 infusion"
                },
                {
                    "measure": "Proportion of participants receiving iron chelation therapy over time",
                    "timeFrame": "EDIT-301 infusion (Day 0) through up to 24 months post EDIT-301 infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\nDiagnosis of Transfusion Dependent B-Thalassemia as defined by:\n\n* Documented homozygous \u03b2-thalassemia or compound heterozygous \u03b2-thalassemia including \u03b2-thalassemia/hemoglobin E (HbE) based on historical data in medical records, and\n* History of at least 100 mL/kg/year or 10 U/year of packed red blood cell (RBC) transfusions in the 2 years prior to signing informed consent\n* Clinically stable and eligible to undergo autologous HSCT\n* Karnofsky Performance Status \u2265 70\n\nKey Exclusion Criteria:\n\n* Available 10/10 human leukocyte antigen (HLA)-matched related donor\n* Prior HSCT or contraindications to autologous HSCT\n* Participants with associated a history of \u03b1-thalassemia and \\> 1 alpha chain deletion, or alpha multiplications as documented in medical records\n* Participants with a history of other inherited hemoglobinopathy or thalassemic mutation (Hb S, C, D or other) as documented in medical records\n* Prior receipt of gene therapy\n* Inadequate bone marrow function, as defined by white blood cell count of \\< 3 x 10\\^9/L or a platelet count \\< 100 x 10\\^9/L (without hypersplenism), per investigator judgement\n* Inadequate organ function\n* Advanced liver disease\n* Any prior or current malignancy, or immunodeficiency disorder,\n* Immediate family member with a known or suspected Familial Cancer Syndrome\n* Clinically significant and active bacterial, viral, fungal, or parasitic infection",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "35 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Editas Medicine Clinical Trial Team",
                    "role": "CONTACT",
                    "phone": "617-401-9007",
                    "email": "Patients@editasmed.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of California San Francisco",
                    "status": "RECRUITING",
                    "city": "Oakland",
                    "state": "California",
                    "zip": "94609",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.80437,
                        "lon": -122.2708
                    }
                },
                {
                    "facility": "University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55410",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "Columbia University Medical Center - Department of Pediatrics",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Columbia University Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Children's Hospital of Philadelphia",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Centre-University Health Network",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013789",
                    "term": "Thalassemia"
                },
                {
                    "id": "D000017086",
                    "term": "beta-Thalassemia"
                },
                {
                    "id": "D000006453",
                    "term": "Hemoglobinopathies"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000745",
                    "term": "Anemia, Hemolytic, Congenital"
                },
                {
                    "id": "D000000743",
                    "term": "Anemia, Hemolytic"
                },
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16557",
                    "name": "Thalassemia",
                    "asFound": "Thalassemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19408",
                    "name": "beta-Thalassemia",
                    "asFound": "Beta Thalassemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9539",
                    "name": "Hemoglobinopathies",
                    "asFound": "Hemoglobinopathies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9547",
                    "name": "Hemolysis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4073",
                    "name": "Anemia, Hemolytic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4075",
                    "name": "Anemia, Hemolytic, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T5622",
                    "name": "Thalassemia",
                    "asFound": "Thalassemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T737",
                    "name": "Beta-thalassemia",
                    "asFound": "Beta Thalassemia",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M5336",
                    "name": "Busulfan",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}